Effectiveness of alitretinoin in severe chronic hand eczema: PASSION, a real-world observational study

References

• Coenraads PJ, Nater JP, van der Lende R. Prevalence of eczema and other dermatoses of the hands and arms in the Netherlands. Association with age and occupation. Clin Exp Dermatol. 1983;8:495–503.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Duh MS, Chang J, et al. A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organisation. Cutis. 2006;77:385–92.
   PubMed Web of Science ®Google Scholar
• Meding B, Jarvholm B. Hand eczema in Swedish adults - changes in prevalence between 1983 and 1996. J Invest Dermatol. 2002;118:719–23.
   PubMed Web of Science ®Google Scholar
• Diepgen TL. Occupational skin-disease data in Europe. Int Arch Occup Environ Health. 2003;76:331–8.
   PubMed Web of Science ®Google Scholar
• Coenraads PJ, Van Der Walle H, Thestrup-Pedersen K, et al. Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis. Br J Dermatol. 2005;152:296–301.
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Agner T, Aberer W, et al. Management of chronic hand eczema. Contact Dermatitis. 2007;57:203–10.
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema – short version. J Dtsch Dermatol Ges. 2015;13:77–84.
   PubMed Web of Science ®Google Scholar
• Coenraads PJ, Diepgen TL. Risk for hand eczema in employees with past or present atopic dermatitis. Int Arch Occup Environ Health. 1998;71:7–13.
   PubMed Web of Science ®Google Scholar
• Cvetkovski RS, Zachariae R, Jensen H, et al. Quality of life and depression in a population of occupational hand eczema patients. Contact Dermatitis. 2006;54:106–11.
   PubMed Web of Science ®Google Scholar
• Gola M, D'Erme AM, Milanesi N, et al. Effects of alitretinoin on quality of life of patients having chronic hand eczema: an observational study. Dermatitis. 2013;24:166–9.
   PubMed Web of Science ®Google Scholar
• Augustin M, Kuessner D, Purwins S, et al. Cost-of-illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany. Br J Dermatol. 2011;165:845–51.
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Purwins S, Posthumus J, et al. Cost-of-illness analysis of patients with chronic hand eczema in routine care in Germany: focus on the impact of occupational disease. Acta Derm Venereol. 2013;93:538–43.
   PubMed Web of Science ®Google Scholar
• Apfelbacher CJ, Akst W, Molin S, et al. CARPE: a registry project of the German Dermatological Society (DDG) for the characterization and care of chronic hand eczema. J Dtsch Dermatol Ges. 2011;9:682–8.
   PubMed Web of Science ®Google Scholar
• Soost S, Abdollahnia M, Kostev K, et al. Topical therapy of hand eczema - analysis of the prescription profile from dermatologists in private practice. J Dtsch Dermatol Ges. 2012;10:180–4.
   PubMed Web of Science ®Google Scholar
• Stiefel. Alitretinoin (Toctino®) Summary of Product Characteristics. Available from https://www.medicines.org.uk/emc/medicine/21177. Accessed March 1, 2015.
   Google Scholar
• Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13:e1–22.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24:1–20.
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158:808–17.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Graff O, Hamedani AG. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. J Drugs Dermatol. 2014;13:1198–204.
   PubMed Web of Science ®Google Scholar
• Dirschka T, Reich K, Bissonnette R, et al. An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids. Clin Exp Dermatol. 2011;36:149–54.
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Pfarr E, Zimmermann T. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012;92:251–5.
   PubMed Web of Science ®Google Scholar
• Yang Y, Brazier J, Longworth L. EQ-5D in skin conditions: an assessment of validity and responsiveness. Eur J Health Econ 2015;16:927–39.
   PubMed Web of Science ®Google Scholar
• Konig HH, Bernert S, Angermeyer MC. Health status of the German population: results of a representative survey using the EuroQol questionnaire. Gesundheitswesen. 2005;67:173–82.
   PubMed Web of Science ®Google Scholar
• Greiner WCC. Der EQ-5D der EuroQol-Gruppe. In: Schöffski OS, J. Matthias Graf, eds. Gesundheitsökonomische Evaluationen. Berlin, Heidelberg: Springer, 2007. p 403–14.
   Google Scholar
• Kalb RE, Blauvelt A, Sofen HL, et al. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol. 2013;12:874–80.
   PubMed Web of Science ®Google Scholar
• Norlin JM, Steen Carlsson K, Persson U, et al. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology. 2012;225:326–32.
   PubMed Web of Science ®Google Scholar
• Berger K, Ehlken B, Kugland B, et al. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3:511–18.
   PubMedGoogle Scholar
• Diepgen TL, Scheidt R, Weisshaar E, et al. Cost of illness from occupational hand eczema in Germany. Contact Dermatitis. 2013;69:99–106.
   PubMed Web of Science ®Google Scholar
• Streiner D, Geddes J. Intention to treat analysis in clinical trials when there are missing data. Evid Based Ment Health. 2001;4:70–1.
   PubMedGoogle Scholar